We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00813956
Recruitment Status : Completed
First Posted : December 23, 2008
Last Update Posted : March 17, 2016
Breast Cancer Research Foundation
Information provided by (Responsible Party):